Clinical Trials Directory

Trials / Unknown

UnknownNCT01024283

Analysis of Pharmacodynamic Changes With AUY922A, an HSP90 Inhibitor

Analysis of Pharmacodynamic Changes Associated With the Administration of the Heat Shock Protein 90 Inhibitor AUY922A in Patients With Advanced Solid Malignancies

Status
Unknown
Phase
Study type
Observational
Enrollment
25 (estimated)
Sponsor
Royal Marsden NHS Foundation Trust · Academic / Other
Sex
All
Age
16 Years
Healthy volunteers
Not accepted

Summary

The principal research objective of this additional research protocol is to support the collection, storage and use of tumour and surrogate (peripheral blood mononuclear cells - PBMNCs). The objective of this study is to perform assays to study pharmacodynamic (PD) markers that confirm target modulation.

Detailed description

Study objectives - 1. Evaluation of HSP70, p-ERK, ERK, p-AKT and AKT in peripheral blood mononuclear cells (PBMNC). Evaluation of p-AKT and AKT will be done by commercially available Meso Scale Discovery (MSD) enzyme linked immunosorbent assay (ELISA) kits, while HSP70 will be studied using ELISA techniques developed within the Institute of Cancer Research. 2. Evaluation of HSP70, p-AKT, AKT, p-ERK, ERK, HER-2 and p-HER2 in tumour tissue. Evaluation of p-AKT, AKT, p-ERK, ERK, HER-2 and p-HER2 will be done by commercially available MSD ELISA kits, while HSP70 will be studied using ELISA techniques developed within the Institute of Cancer Research. Study design - All patients entering the open label, phase I dose escalation and phase II expansion arms of AUY922A at the Royal Marsden Hospital will be asked to participate in this study. Patients will not have to attend additional appointments for this study and samples will be taken during visits for the planned Phase I/II clinical trial. Consent to donate samples for this research study is voluntary and patients will be asked to sign a separate consent form.

Conditions

Timeline

Start date
2008-12-01
Primary completion
2013-08-01
Completion
2013-08-01
First posted
2009-12-02
Last updated
2009-12-02

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT01024283. Inclusion in this directory is not an endorsement.